Dogwood Therapeutics Inc (DWTX)

$1.56 -0.15 (-8.77%)
Market Cap 57.12M
Revenue (ttm) 0.00
Net Income (ttm) -34.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 200,900
Avg Vol 73,072
Day's Range N/A - N/A
Shares Out 33.40M
Stochastic %K 3%
Beta 2.05
Analysts Strong Sell
Price Target $14.00

Company Profile

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a co...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 620 8655
Website: dwtx.com
Address:
44 Milton Avenue, Alpharetta, United States
Drainomight
Drainomight Apr. 16 at 7:51 PM
$DWTX my guess is the trust is gone with this company. We’re gonna need something to hit the market before any movement happens.
0 · Reply
hammerfall43
hammerfall43 Apr. 16 at 2:17 PM
$DWTX r/s coming end 2026
0 · Reply
JAG_2_Trade
JAG_2_Trade Apr. 16 at 12:42 PM
$DWTX Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
0 · Reply
CHItraders
CHItraders Apr. 15 at 1:02 PM
$DWTX Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 15 at 1:01 PM
$DWTX Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
0 · Reply
biotrade123
biotrade123 Apr. 15 at 10:31 AM
$DWTX PM vol 235k?? what news??
1 · Reply
Drainomight
Drainomight Apr. 9 at 6:46 PM
$DWTX let’s go dogwood
0 · Reply
Drugtrade
Drugtrade Apr. 7 at 1:54 PM
$DWTX $TCRX $ALGS nice market to play picks a few i like atm
0 · Reply
KOWALSK1
KOWALSK1 Apr. 6 at 3:32 PM
$DWTX waiting you to move 😁👑
0 · Reply
KOWALSK1
KOWALSK1 Apr. 6 at 6:50 AM
$DWTX Dogwood ✅️ BUY ZONE 2.05 to 1.77 ✋️ RISK BELOW 1.59 🎯 PT. 2.31 2.67 2.89 3.07 3.37 + UP Follow for more
0 · Reply
Latest News on DWTX
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Apr 15, 2026, 9:00 AM EDT - 1 day ago

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 18, 2026, 8:30 AM EDT - 4 weeks ago

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

Feb 2, 2026, 8:30 AM EST - 2 months ago

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

Jan 12, 2026, 8:30 AM EST - 3 months ago

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

Dec 22, 2025, 10:15 AM EST - 4 months ago

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045

Dec 2, 2025, 8:00 AM EST - 4 months ago

Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045

Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025

Nov 11, 2025, 8:45 AM EST - 5 months ago

Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025

Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 8:45 AM EST - 5 months ago

Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Oct 30, 2025, 9:15 AM EDT - 6 months ago

Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

Oct 14, 2025, 8:45 AM EDT - 6 months ago

Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

Oct 7, 2025, 8:45 AM EDT - 6 months ago

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

Sep 29, 2025, 7:15 AM EDT - 7 months ago

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:15 AM EDT - 8 months ago

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 9:00 AM EDT - 8 months ago

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Aug 7, 2025, 1:08 PM EDT - 9 months ago

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Aug 6, 2025, 9:15 AM EDT - 9 months ago

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

Jun 3, 2025, 9:15 AM EDT - 11 months ago

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

May 8, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

May 1, 2025, 8:30 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Apr 11, 2025, 9:15 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Apr 3, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Mar 31, 2025, 3:45 PM EDT - 1 year ago

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Mar 18, 2025, 8:45 AM EDT - 1 year ago

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Mar 13, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Oct 7, 2024, 7:05 AM EDT - 1 year ago

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Aug 8, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Aug 1, 2024, 9:41 AM EDT - 1 year ago

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

Jul 23, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 22, 2024, 1:30 PM EDT - 2 years ago

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 19, 2024, 8:53 PM EDT - 2 years ago

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 17, 2024, 4:10 PM EDT - 2 years ago

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:45 AM EDT - 2 years ago

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

May 2, 2024, 9:15 AM EDT - 2 years ago

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Mar 26, 2024, 9:15 AM EDT - 2 years ago

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 29, 2024, 9:15 AM EST - 2 years ago

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Feb 28, 2024, 9:15 AM EST - 2 years ago

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Jan 22, 2024, 9:00 AM EST - 2 years ago

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Jan 2, 2024, 7:05 AM EST - 2 years ago

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Nov 6, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Oct 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Sep 18, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Sep 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Aug 14, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Aug 9, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Jul 17, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 25, 2023, 4:05 PM EDT - 3 years ago

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

May 15, 2023, 7:05 AM EDT - 3 years ago

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

Drainomight
Drainomight Apr. 16 at 7:51 PM
$DWTX my guess is the trust is gone with this company. We’re gonna need something to hit the market before any movement happens.
0 · Reply
hammerfall43
hammerfall43 Apr. 16 at 2:17 PM
$DWTX r/s coming end 2026
0 · Reply
JAG_2_Trade
JAG_2_Trade Apr. 16 at 12:42 PM
$DWTX Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
0 · Reply
CHItraders
CHItraders Apr. 15 at 1:02 PM
$DWTX Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 15 at 1:01 PM
$DWTX Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
0 · Reply
biotrade123
biotrade123 Apr. 15 at 10:31 AM
$DWTX PM vol 235k?? what news??
1 · Reply
Drainomight
Drainomight Apr. 9 at 6:46 PM
$DWTX let’s go dogwood
0 · Reply
Drugtrade
Drugtrade Apr. 7 at 1:54 PM
$DWTX $TCRX $ALGS nice market to play picks a few i like atm
0 · Reply
KOWALSK1
KOWALSK1 Apr. 6 at 3:32 PM
$DWTX waiting you to move 😁👑
0 · Reply
KOWALSK1
KOWALSK1 Apr. 6 at 6:50 AM
$DWTX Dogwood ✅️ BUY ZONE 2.05 to 1.77 ✋️ RISK BELOW 1.59 🎯 PT. 2.31 2.67 2.89 3.07 3.37 + UP Follow for more
0 · Reply
Djrosso
Djrosso Mar. 30 at 2:45 PM
$DWTX seems like someone keeps dropping it by about 6 percent per day… i am confused with the price action. no bad news, no dilution, yet it keeps falling.
0 · Reply
Drugtrade
Drugtrade Mar. 30 at 2:25 PM
$DWTX back in here lets see what happens
0 · Reply
Djrosso
Djrosso Mar. 30 at 2:02 AM
$DWTX why does it keep falling in no bad news and no dilution before results
2 · Reply
hammerfall43
hammerfall43 Mar. 25 at 3:48 PM
$DWTX 1$ coming
1 · Reply
ZacksSCR
ZacksSCR Mar. 23 at 3:23 PM
$DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26 https://buff.ly/Zs99Z7b
0 · Reply
Drainomight
Drainomight Mar. 23 at 2:56 PM
$DWTX
0 · Reply
ChartChartist
ChartChartist Mar. 22 at 11:53 PM
$AGIG waiting $DWTX setting up nicely $MTEK should do more $TPST multi bottoms But top play idea for week $GURE everyones on gure; top play. Oil. Nano. Hot.
2 · Reply
Drainomight
Drainomight Mar. 20 at 8:21 PM
$DWTX nice volume today more than expected
0 · Reply
topstockalerts
topstockalerts Mar. 20 at 7:27 PM
$DWTX biotech-style mover, reacts hard to updates. Can go from flat to volatile real quick.
0 · Reply
tboykeyhoang
tboykeyhoang Mar. 20 at 6:10 PM
$DWTX it has good progress and good report this quater!!
0 · Reply
Kakahi69
Kakahi69 Mar. 20 at 3:20 PM
$DWTX on close watch
0 · Reply
ArloPalaceTrades
ArloPalaceTrades Mar. 16 at 11:23 PM
$DWTX who remembers this ran 500% on 1 candle insane looll
1 · Reply